More articles about Policy & Legislation

The Ventana PD-L1 assay was approved as a complementary diagnostic for bladder cancer patients being considered for treatment with the immunotherapy Imfinzi. 

The omnibus spending bill, which has garnered bipartisan support, follows the White House's call to trim the NIH budget by $1.2 billion.

S.794 would require Medicare contractors to hold public meetings and disclose the rationale and evidence underlying an LCD at the start of the process.

The proposed cut comes on the heels of a budget proposal that would reduce the NIH's fiscal year 2018 budget by 20 percent.

The draft bill, based on a proposal developed by a coalition of Dx manufacturers and labs, would split oversight responsibilities across the FDA, CMS, and states. 

Enrolling more participants from groups underrepresented in biomedical research is a laudable goal, but the current administration's policies may make it hard to achieve.

In his report, President Trump called for a reduction in National Institutes of Health funding, along with a reorganization of the agency.

Any short-term gains the bill may have on encouraging healthier lifestyles wouldn’t be worth the crippling effects it could have on the genomics field, leaders in the space said.

Some 50 groups have signed a letter expressing strong opposition to a bill that would allow workplace wellness programs to collect employees' genetic information.

The authors framed their report as a guidebook to help regulatory agencies across the globe coordinate "consistent" rules while allowing for societal differences.

Researchers fear the executive order will have long-lasting effects on the US' ability to recruit top talent, and will make the country less attractive as an international conference venue.

The organization cited ethical concerns and technological limitations surrounding CRISPR and other gene-editing approaches.

The agency expects existing programs to guide its regulation, adding that modified portions of animal genomes would be considered drugs.

The Genomics Evidence Neoplasia Information Exchange aims to provide insights through the analysis of data from tens if not hundreds of thousands of patient results.

The law contains provisions that proponents say will advance precision medicine and speed new tests to market, but critics worry if this will come at a cost to public health.

Key provisions of the legislation include additional funding for key National Institutes of Health programs, as well as a streamlining of the US Food and Drug Administration's approval process.

New York Governor Andrew Cuomo and New York City Mayor Bill de Blasio unveiled two initiatives that will provide funding and tax incentives for life sciences research and industry.

After passing the House of Representatives last week, the legislation is now set to go before President Barack Obama, who said he will sign it into law.

The case is being framed as either upholding a strong patent regime or dealing a blow to US-based manufacturing as part of the global supply chain.

With strong bipartisan support, the White House indicated that President Barack Obama will sign the legislation once it receives Senate approval.

Pages

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.